FOSUN PHARMA
复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to the Progress of Drug Clinical Trials of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
26 November 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the nonexecutive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Stock code: 600196 Stock abbreviation: Fosun Pharma Announcement No.: Lin 2021-163

Bond code: 143020 Bond abbreviation: 17 Fosun 01

Bond code: 143422 Bond abbreviation: 18 Fosun 01

Bond code: 155067 Bond abbreviation: 18 Fosun 02

Bond code: 155068 Bond abbreviation: 18 Fosun 03

Bond code: 175708 Bond abbreviation: 21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Progress of Drug Clinical Trials of a Subsidiary

The board of directors of the Company and all members of the Board warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復星醫藥產業發展有限公司) ("**Fosun Pharmaceutical Industrial**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**"), has initiated a Phase II clinical study of FCN-159 tablets (the "**Investigational New Drug**") for the treatment of neurofibromatosis type I in the PRC (excluding Hong Kong, Macau and Taiwan regions, hereinafter the same).

II. Research Progress of the Investigational New Drug

The Investigational New Drug is a novel small molecule chemical researched and developed by the Group (i.e. the Company and its subsidiaries/units, the same below). It is a selective MEK1/2 inhibitor and is intended to be developed for the treatment of advanced solid tumor and neurofibromatosis type I. As at the date of this announcement,

In addition to the Phase II clinical study initiated in China for the treatment of neurofibromatosis type I, the Investigational New Drug to be used for the treatment of advanced melanoma harboring NRAS aberrant and NRAS mutation is under phase I clinical trial stage in the PRC and is clinically approved in the United States for the treatment of adult and pediatric patients with neurofibromatosis type I (NF1).

As at the date of this announcement, the MEK1/2 selective inhibitors which have been launched globally include Trametinib from Novartis Pharma Schweiz AG, Cobimetinib from Roche Pharma (Schweiz) AG, Binimetinib from Pfizer Inc. and Selumetinib from AstraZeneca PLC etc., of which: Trametinib from Novartis Pharma Schweiz AG was launched in the PRC in 2019. According to the latest data from IQVIA MIDAS™ (provided by IQVIA, a global leading provider of professional information and strategic consulting services for the pharmaceutical and health industry), the sales of MEK1/2 selective inhibitor across the world in 2020 amounted to approximately US$1.18 billion. According to the data from IQVIA CHPA (provided by IQVIA, the data of IQVIA CHPA represents the drug sales market in hospitals with more than 100 beds in the PRC, actual sales of different drugs may vary to varying degrees from the data of IQVIA CHPA due to the layout of the respective distribution channels), the sales of Trametinib in the PRC was approximately RMB 0.61 million in 2020, the sales of Trametinib in the PRC was approximately RMB 40.7 million in the first three quarters of 2021.

As at October 2021, the Group has cumulatively invested in the R&D of the Investigational New Drug in an aggregate amount of RMB108.07 million (unaudited).

III. Risk Warning

There are certain risks in the R&D of new drugs based on our experience, for example, clinical trials may be terminated due to issues such as safety and/or efficacy.

Under the relevant laws and regulations of the PRC, the Investigational New Drug for the treatment of neurofibromatosis type I is subject to a series of clinical studies carried out in the PRC and approval by the competent national drug review department before they come onto the market.

The R&D and marketing of new drugs is a long-term task involving various

uncertainties. Investors should be aware of the investment risks.

Announcement is hereby given.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

26 November 2021